Written Evidence Nov. 29 2023
Inquiry: Men's healthFound: IMH0040 - Men's health Prostate Cancer UK Written Evidence
Written Evidence Jan. 24 2024
Inquiry: Men's healthFound: Prostate Cancer Overview Prostate cancer is the most common cancer in men in England, with 36,016
Jan. 30 2024
Source Page: Tax funding of cancer treatment: FOI reviewFound: Tax funding of cancer treatment: FOI review
Feb. 06 2024
Source Page: Children and Young People Cancer Taskforce launched to save livesFound: Children and Young People Cancer Taskforce launched to save lives
Written Evidence Nov. 29 2023
Inquiry: Men's healthFound: The campaign is run by phs Group, the leading hygiene services provider in the UK, and Prostate Cancer
Asked by: Lloyd Russell-Moyle (Labour (Co-op) - Brighton, Kemptown)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, which NHS bodies have a role in the consideration of Abiraterone for inclusion in the drug repurposing programme for the treatment of locally advanced high-risk non-metastatic prostate cancer; and what the remit of each body is in that process.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The national, multi-agency Medicines Repurposing Programme is hosted and funded by NHS England and is overseen by a steering group, including decision-making members from the Department, the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence, the National Institute for Health and Care Research, and NHS England. Each of the national agencies brings a different contribution to the programme, in line with their respective regulatory and statutory responsibilities.
The programme steering group has not discussed adopting abiraterone for high-risk, non-metastatic hormone sensitive prostate cancer into the repurposing programme. This is because an off-label clinical commissioning policy covering the off-label use of abiraterone in this indication is being developed by NHS England and, in this case, NHS England considers this to be the most appropriate route to support a decision on routine patient access in the National Health Service. The policy is being considered through the established process in line with the current methods, which are available at the following link:
Written Evidence Nov. 29 2023
Inquiry: Men's healthFound: cancer is the most common cancer in men and 1 in 8 men will get prostate cancer in their lifetime
Mentions:
1: Nick Fletcher (Con - Don Valley) Just this weekend, they announced help with issues that so many men face: prostate cancer screening, - Speech Link
2: Jim Shannon (DUP - Strangford) He touched on some of the things I wish to speak about: suicide rates, prostate cancer and loneliness - Speech Link
3: Jim Shannon (DUP - Strangford) recognises that prostate cancer is a killer. - Speech Link
4: Abena Oppong-Asare (Lab - Erith and Thamesmead) We also know about the well-recognised high rate of prostate cancer among black men. - Speech Link
5: Maria Caulfield (Con - Lewes) The prostate research will dramatically change outcomes for men. On the point made by the hon. - Speech Link
Mentions:
1: Lord Dubs (Lab - Life peer) We are talking about drugs for the treatment of cancer and comments from the pharmaceutical industry - Speech Link
2: Lord Cunningham of Felling (Lab - Life peer) the performance of the National Health Service and others in respect of research into and finding solutions - Speech Link
3: Lord Markham (Con - Life peer) My noble friend Lord Moylan has also raised pancreatic cancer a number of times. - Speech Link
4: Lord Markham (Con - Life peer) A study was produced by the Pharmaceutical Research and Manufacturers of America looking at supply issues - Speech Link
Found: • To provide opportunities for MSPs to learn about the latest Scottish and international cancer research